Can OX40 Agonists Increase the Potency of COVID-19 Vaccines?

Authors

Andrew D Weinberg, Earle A. Chiles Research Institute, Providence Cancer Institute; Laboratory of Basic Immunology, Providence Health & Services; CSO, AgonOxFollow

Document Type

Abstract

Publication Date

10-8-2020

Publication Title

8th Annual Immuno-Oncology Virtual Summit, Oct 6-8, 2020

Keywords

2019-nCoV

Abstract

Eliciting a potent long-lasting immune response (e.g. Ab, CD4, and CD8 T cells) against the SARS-CoV-2 virus with a vaccine will most likely be essential to reduce morbidity and mortality during future waves of viral propagation. To this end our lab has been working on a way to increase the potency of vaccines for 20 years through engagement of the TNF-receptor family member, OX40. This talk will cover the data generated over the last 20 years in vaccinated hosts boosted with OX40 agonists and present preliminary data in mice injected with a COVID-19 vaccine w/wo OX40 agonists.

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Department

Infectious Diseases

Recommended Citation

Weinberg, Andrew D, "Can OX40 Agonists Increase the Potency of COVID-19 Vaccines?" (2020). Articles, Abstracts, and Reports. 4085.
https://digitalcommons.providence.org/publications/4085